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Type  1 Diabetes Mellitus
a  b  s  t  r  a  c  t
Aim  of the  study:  Previous  studies  have  found  no significant  improvements  in  glycated  hemoglobin
(HbA1c),  while  using  Continuous  Glucose  Monitoring  (CGM),  with  children  and  adolescents.  The  aim
of  this  paper  is to measure  the change  in  HbA1c,  and  the Coefficient  of  Variation  in  glucose  levels,  when
using  CGM,  once  the  effect  of  other  relevant  variables,  such  as  gender,  actual  age,  the  years  the  patient  has
had  diabetes,  use  of  an  insulin  pump,  the  presence  of autoimmune  disease,  other  associated  pathologies,
and  weekly  hours  of  exercise,  are  controlled  for.
Methods: This  is a retrospective  study  that  uses  a linear  regression  model.  Data  was  collected  from  Type 1
Diabetes  Mellitus  (T1DM),  children  diagnosed  between  2003  and  2017  in  the  Pediatric  Unit  for  DiabetesGlycosylated  hemoglobin A
Coefficient of Variation
Linear  regression model
in  Zaragoza,  Spain.  We  used  a linear  regression  and  the  method  of  estimation  is Ordinary  Least  Squares.
Results: Results  show  that  the  use  of CGM  decreased  the  HbA1c  value  by  3.5%  and  the  Coefficient  of
Variation  by  14%.
Conclusions:  The  implication  of these  results  is that  this  device  helped  in  the management  of  diabetes,
although  more  research  is  needed  to distinguish  between  different  devices  in terms  of  their efficacy.












There are two steps to maintain blood glucose within optimal
range for a Type 1 Diabetes Mellitus patient: (1) To know the value
in real time and (2) to provide the necessary insulin. The main
advantages of Continuous Glucose Monitoring (CGM) are the con-
tinuous measurement of glucose, which shows all the peaks in
values not seen with discontinuous measures, as well as decreasing
the number of skin punctures [1], and increasing patient satisfac-
tion [2]. The main disadvantage is a lack of accuracy which has
been noted in several articles [3], although new models and algo-
rithms have improved precision [4]. One key factor in the use of
CGM is patient education, so patients with varying levels of exper-
tise in diabetes care can present different results, independent of
the glucose-measuring device used [5].
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Care Diab., https://doi.org/10.1016/j.pcd.2020.10.005The result of a good control for diabetes in the long-term is quan-
ified through a low value of HbA1c, although new research also
akes into consideration a low Coefficient of Variation of glucose
evels [6].
Despite the fact that many recent papers find a high correlation
etween the use of CGM and the value of HbA1c [7], some studies
ave reached different conclusions [8]. However most of them have
sed descriptive statistics to reach this conclusion [9].
Given  that the HbA1c levels and the Coefficient of Variation in
he child population are related to variables such as age, sex, and
ears of experience with diabetes [10], among others, the improve-
ent in HbA1c levels in this population is also due to the effect of
hese variables in addition to the use of the CGM itself. For this rea-
on, by means of a linear regression model, we planned to study
he effect of the use of CGM in the improvement of the metabolic
ontrol of children with type 1 diabetes, isolating the effect of other
ariables such as gender, age, years the patient has had diabetes,
se of an insulin pump, the presence of autoimmune disease, other
ssociated pathologies, and weekly hours of exercise.
The aim of the paper is to measure the effect of using CGM
n changes in HbA1c and the Coefficient of Variation in the Pedi-
erved.
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atric Unit of Aragón. The plan to introduce this device in the Public
Regional Health System made it necessary to evaluate the results.
The CGM devices were used by some of the patients in the sample
(who paid their own costs), and the regional government’s project
was to finance the use by the Regional Health System for pediatric
patients without additional cost to the patients.
The paper is organized as follows. Section 2 presents the
database and methodology on which we based the empirical study.
Section 3 presents the regression model. In Section 4, we  summa-
rize the main conclusions.
2.  Materials and Methods
2.1.  Database
The database consists of data collected from September to
December 2017 from patient-and-family clinical data, for subjects
diagnosed with Type 1 Diabetes Mellitus, between 2003 and 2017,
in the Pediatric Unit for Diabetes in Zaragoza, Spain. This Unit
controlled the training of patients and their families, all of whom
participated in the same training courses and received the same
guidelines to manage the device. Questionnaires were completed
by doctors and patient-caregivers and the information was  sum-
marized in an anonymized database. Parents of patients were fully
informed and gave their consent. The data showed that more than
50% of children used CGM in the Diabetic Pediatric Unit of Aragón,
and almost all of them used it routinely.
A statistical summary of the variables used in our study can
be found in Table 1. The variables considered were reported by
doctors and by a glucose meter, except for the time devoted to
exercise, while hypoglycemic information was provided by patient-
caregivers. Despite the potential time lag these measures present
with respect to the medical variables, they can still be considered
a good proxy in the regression analysis. We  considered two  types
of patients: (1) those with CGM whose information corresponds to
the time when each patient began to use the device (previous vari-
ables are 6 and 3 months before that time, and post variables are 3
and 6 months after the use of CGM); (2) those without CGM whose
information relates to the moment the questionnaire was  com-
pleted (previous variables are the two last values collected, from
September to December 2017). For the analysis, age and experience
over time were categorized with similar ranges used in previous
papers. [11]
The  questions were answered by 120 individuals, from a tar-
get population of 256. The Pediatric Unit treats approximately 85%
of the children diagnosed with Type 1 diabetes in this geographic
area. For the regression model, weights were used to adjust for dif-
ferences in age, sex and experience over time between the sample
and the target population.
In  order to capture the evolution of HbA1c we created two
variables for every child in the sample: HbA1cPre and HbA1cPost.
HbA1cPre is the mean of the two HbA1c values prior to the use of
CGM for those using the continuous device, and the last value of
HbA1c before answering the questionnaire for those without CGM.
HbA1cPost is the mean of the two HbA1c values after using CGM,
and the value of HbA1c collected from September to December
2017 for those without CGM. The ratio between both variables,
HbA1CPost over HbA1CPre, measures the difference between them
in relative terms and allows us to measure the growth for every
patient. For those with CGM it captures the changes produced by
the use of CGM, and for those without CGM it allows us to capture
the variability of this parameter (HbA1c differs for each patient in
different time periods).
We  have used the Coefficient of Variation provided by the doc-
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ith  CGM, it is the variation coefficient after 6 months of using
GM, or after three months if that information was not available.
.2.  Statistical and regression analysis
Data were analyzed with the statistical package STATA 14 [12].
e used a linear regression and the method of estimation was  Ordi-
ary Least Squares (OLS), which allowed us to measure the isolated
ffect of the CGM, taking into account that the sample is hetero-
eneous in terms of age, gender, and other characteristics. Two
odels were used: one to explain the HbA1c change and a sec-
nd to explain the Coefficient of Variation of glucose levels. The
oefficients associated with all the explanatory variables consid-
red: gender, age, years the patient has had diabetes, that is years
f experience with diabetes [13], type of treatment [14] time spent
n exercise, other pathologies, and the use of CGM. We  measured
he effect of each explanatory variable on the endogenous variables
HbA1c change and Coefficient of Variation), in order to control for
he effect of the other variables.
The two models fulfilled our main requirements: normality of
esiduals, no misspecification of the model, and coefficients robust
o heteroskedasticity.
. Results
Table 2 shows the coefficients, Coef, for the same exogenous
ariables used to explain the two endogenous variables: HbA1c
atio and Coefficient of Variation, along with the p-value, P>|t|,
o measure the significance of the coefficient. The Coefficients
f Variation use logarithms in order to interpret the rate of
rowth. For categorical exogenous variables (insulin pump use,
GM, autoimmune diseases and associated pathology), the cor-
esponding coefficient explains the variation in the ratio due to
aving that characteristic vs. not having it (for example, how much
he HbA1c ratio varies when wearing an insulin pump vs. not wear-
ng a pump). Regarding the gender variable, the reference group is
ale, so the coefficients explain how the dependent variables vary
hen the patient is female versus male. Finally, for age and years
f experience with diabetes, which are categorical variables with
ore than two  categories, the lower levels of these variables (the
atient’s age from 0 to 5 years and less than one year of disease
volution) have been used as reference ranges in the models. Thus,
n these variables the coefficients indicate how the dependent vari-
bles (HbA1c of Coefficient of Variation) vary when comparing the
eference range with the other categories (for example, how much
ould the HbA1c ratio vary in patients between 1 and 6 years old
ith respect to those from 0 to 5 years, if all the other exogenous
ariables remained stable).
Gender, any associated pathology, and hours of weekly exercise
ad no significant effects on the HbA1c Ratio, nor on the Coefficient
f Variation when the other explanatory variables were introduced
nto the model, as shown by the significance of the coefficients in
olumn P>|t|.
The  model indicated that being in the age range of 6 to 10 years
ld increased the HbA1c Ratio by 0.15, while being more than 10
ears old increased that same ratio by 0.12. Age did not affect the
oefficient of Variation.
Those  patients who  had had the condition for up to five years
howed an improvement of 19% in the Coefficient of Variation, rel-
tive to those patients in their first year of diabetes.Paradoxically, the use of an insulin pump increased the Coeffi-
ient of Variation. Perhaps it is because the pump is more strongly
ecommended for patients with a history of poor diabetes control
n the Pediatric Diabetes Unit of Zaragoza.
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Table 1
Summary statistics.
Metabolic variables Obs Mean Std. Dev. Min  Max
HbA1cPOST (%[mmol/mol])a 117 7.3% 0.9112 5.1[33] 10.4 [90]
HbA1cPRE(%[mmol/mol])b 118 7.4% 1.0217 5.4 [36] 12.1 [109]
HbA1cRatioc 117 0.99 0.0831 0.63 1.19
HbA1cPOST- HbA1cPRE 117 −0.14 0.7273 −4.5 1.1
HbA1c  growth 117 −1.36% 8.3138 −37.19% 18.97%
Coefficient  of VariationPOSTd 72 41.37 7.2436 23.03 65.08
Coefficient  of VariationPREe 72 41.51 7.7353 13.01 57.58
Mean  GlycaemiaPOSTf (mg/dl) 88 165 23.4427 115 271
Mean  GlycaemiaPREg (mg/dl) 88  166 24.0713 115 246
Personal  variables
Female Male
Gender 120 43.33% 56.67%
from 0 to 5 from 6 to 10 more than 10
Age 119 10.92% 34.45% 54.62%
less  than 1 from 1 to 5 from 6 to 10 more than 10
Years  of experience 119 5.04% 67.23% 19.33% 8.40%
Medtronic Dexcom Freestyle No CGM
CGM  120 15.00% 9.17% 28.33% 47.50%
Weekly  exercise (hours) 109 Mean = 6 Std. Dev. = 3.8489
Yes No
CGM 120 52.50% 47.50%
Insulin pump 120 26.67% 73.33%
Autoimmune diseases 118 11.86% 88.14%
Associated pathology 120 14.17% 85.83%
a HbA1c after CGM use or last value for those not using CGM.
b HbA1c prior to CGM use or prior to last value for those not using CGM.
c Ratio between HbA1cPOST and HbA1cPRE
d Coefficient of Variation after CGM use or last value for those not using CGM.
e Coefficient of Variation prior to CGM use or prior to last value for those not using CGM.
f Mean glycaemia after CGM use or last value for those not using CGM.
g Mean glycaemia prior to CGM use or prior to last value for those not using CGM.
Table 2
OLS  model: endogenous variables: HbA1c ratio and Coefficient of Variation of glucose.
HbA1c ratioa Coefficient of Variationb
Coef P > |t| Coef P > |t|
Female −0.0081 0.651 −0.0533 0.175
Age  (reference range 0–5 years)
From 6 to 10 years old 0.1487  0.009 *** −0.0008 0.992
More  than 10 years old 0.1236 0.036 ** 0.0258 0.723
Years  of experience (reference range > 1 years)
From 1 to 5 years 0.0338 0.571 −0.1667 0.061 *
From  6 to 10 years 0.0114 0.851 −0.1226 0.205
More  than 10 years 0.0027 0.967 −0.0747 0.484
Insulin  pump 0.0282 0.105 0.0975 0.059 **
CGM  −0.0359 0.019 ** −0.1402 0.002 ***
Autoimmune  diseases −0.0491 0.002 *** 0.1461 0.003 ***
Associated  pathology 0.0267 0.108 −0.0333 0.29
Hours  of weekly exercise −0.0006 0.752 −0.0065 0.24
cons  0.8594 0 *** 3.9310 0 ***
* p < 0.10.





gender. Using a regression model, it was  possible to establish a fixed
value for the variables that affected the HbA1c and the Coefficient
of Variation of glucose, in order to isolate and measure the effect of*** <0.01.
a N = 106; F (11, 94) = 4.91; R2 = 0.28; Ramsey Ho: no misspecification (p-value) = 
b N = 69; F (11, 57) = 2.78. R2 = 0.33; Ramsey Ho: no misspecification (p-value) = 0.
The presence of an autoimmune disease decreased the HbA1c
Ratio by 0.05, but increased the Coefficient of Variation by 15%.
Finally,  the use of CGM decreased the HbA1c Ratio by 0.036,
which can be interpreted as a change of -3.6%, and the Coefficient of
Variation decreased by 14% when gender, age, years of experience
with diabetes, insulin pump use, other pathologies, and exercise
were considered as explanatory factors.t
3
kewness/Kurtosis tests for normality (p-value) = 0.11.
ewness/Kurtosis tests for normality (p-value) = 0.1.
.  Conclusion
There were variations in the HbA1c or Coefficient of Variation of
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This study demonstrates the positive effect of using CGM in
children with T1DM, in terms of improving the HbA1c and the
Coefficient of Variation supporting the addition of these devices to
the services provided by the Regional Health System. Better con-
trol of diabetes leads to a lower probability of costly complications
(retinopathy, nephropathy, renal failure, etc).
The study has certain limitations:
- There are no values for the Coefficient of Variation and Mean Glu-
cose for the whole sample, because not all patients in the sample
had  a blood glucose meter that provided a mean and a standard
deviation necessary to make those calculations.
-  There are insufficient observations of patients using the three
CGM  devices, Freestyle, Dexcom and Medtronic, to pursue a more
specific  analysis for each brand. A broader sample would allow
us  to evaluate the effectiveness of each device in isolation, rather
than  taking an aggregate evaluation that could be masking impor-
tant  differences between these devices.
5.  Discussion
With respect to HbA1c improvements, some prior studies, [8]
find no significant differences in results, while using CGM, for
patients in the age range of 4 to 9. In our work, a more detailed
age range for children is used and the improvement was  general
for all ages considered. The papers that concluded that HbA1c did
not decrease in children could be capturing the effect of age, rather
than that of the use of CGM, so it was necessary to control for a
range of variables in order to isolate the effect of CGM. Another rea-
son for a different result could be that more than 94% of our sample
used CGM routinely, and some papers associate improvement in
HbA1c with the continuous use of CGM devices [15]. Considering
the Coefficient of Variation, certain studies relate the use of CGM
to a decrease in the Coefficient of Variation [16]. Our results were
similar for the Coefficient of Variation: when other related factors
(gender, age, pathologies, habits, and so on) are considered, the
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